Brain-inspired cheminformatics of drug-target brain interactome, synthesis, and assay of TVP1022 derivatives

Neuropharmacology

Volumn 103, Issue , 2016, Pages 270-278

  Romero Durán, Francisco J ^a,b   Alonso, Nerea ^a   Yañez, Matilde ^a   Caamaño, Olga ^a   García Mera, Xerardo ^a   González Díaz, Humberto ^c,d  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b IMQ Zorrotzaurre Clinic   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d BASQUE FOUNDATION FOR SCIENCE   (Spain)

Author keywords

Alzheimer disease; Artificial neural networks; Asymmetric synthesis; ChEMBL; Chemoinformatics; CNS drug target interactome; CNS drugs; Neuroprotective effects; Rasagiline analogues

Indexed keywords

1 (N PROPARGYLAMINO) 2 INDANOL; 1 (N PROPARGYLAMINO) 2 INDANYL DIETHYLCARBAMATE; 1 (N PROPARGYLAMINO) 2 INDANYL DIMETHYLCARBAMATE; 1 (N,N DIPROPARGYLAMINO) 2 INDANYL ACETATE; 1 (N,N DIPROPARGYLAMINO) 2 INDANYL BENZOATE; 1 (N,N DIPROPARGYLAMINO) 2 INDANYL DIETHYLCARBAMATE; 1 (N,N DIPROPARGYLAMINO) 2 INDANYL DIMETHYLCARBAMATE; CHOLINESTERASE INHIBITOR; MONOAMINE OXIDASE INHIBITOR; RASAGILINE; UNCLASSIFIED DRUG; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ARTICLE; BRAIN CELL; CARBAMOYLATION; CELL VIABILITY; CONTROLLED STUDY; DRUG SYNTHESIS; EMBRYO; NONHUMAN; PRIORITY JOURNAL; RAT; ALGORITHM; ANIMAL; ARTIFICIAL NEURAL NETWORK; BIOLOGY; BRAIN; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; RECEIVER OPERATING CHARACTERISTIC;

ALGORITHMS; ANIMALS; BRAIN; COMPUTATIONAL BIOLOGY; DRUG DELIVERY SYSTEMS; HUMANS; INDANS; NEURAL NETWORKS (COMPUTER); NEUROPROTECTIVE AGENTS; ROC CURVE;

EID: 84953225344     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.12.019     Document Type: Article

References (64)

1. P. Abeijon, X. Garcia-Mera, O. Caamano, M. Yanez, E. Lopez-Castro, F.J. Romero-Duran, and H. Gonzalez-Diaz Multi-target mining of Alzheimer disease proteome with Hansch's QSBR-perturbation theory and experimental-theoretic study of new thiophene isosters of Rasagiline Curr. Drug Targets 2015 Nov 1 [Epub ahead of print] PMID: 26521774
2. N. Alonso, O. Caamano, F.J. Romero-Duran, F. Luan, M.N. Dias Soeiro Cordeiro, M. Yanez, H. Gonzalez-Diaz, and X. Garcia-Mera Model for high-throughput screening of multi-target drugs in chemical neurosciences; synthesis, assay and theoretic study of Rasagiline carbamates ACS Chem. Neurosci. 4 2013 1393 1403
3. N. Alonso, O. Caamano, F.J. Romero-Duran, F. Luan, M. N D. S. C., M. Yanez, H. Gonzalez-Diaz, and X. Garcia-Mera Model for high-throughput screening of multitarget drugs in chemical neurosciences: synthesis, assay, and theoretic study of rasagiline carbamates ACS Chem. Neurosci. 4 2013 1393 1403
4. R.F. Allegri, and A. Guekht Cerebrolysin Improves Symptoms and Delays Progression in Patients with Alzheimer's Disease and Vascular Dementia Drugs Today (Barc). 2012 Prous Science, S.A.U. or its licensors, United States 2012 25 41
5. B. Balaji, S. Hariharan, D.B. Shah, and M. Ramanathan Discovery of potential and selective COX-1 inhibitory leads using pharmacophore modelling, in silico screening and in vitro evaluation Eur. J. Med. Chem. 86 2014 469 480
6. D.J. Bonda, X. Wang, G. Perry, A. Nunomura, M. Tabaton, X. Zhu, and M.A. Smith Oxidative stress in Alzheimer disease: a possibility for prevention Neuropharmacology 59 2010 290 294
7. D. Bonneh-Barkay, N. Ziv, and J.P. Finberg Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells Neuropharmacology 48 2005 406 416
8. G.E.P. Box, and G.M. Jenkins Time Series Analysis 1970 Holden-Day
9. L. Breiman Statistical modeling: the two cultures (with comments and a rejoinder by the author) Stat. Sci. 16 2001 199 231
10. S.N. Bukhari, I. Jantan, V.H. Masand, D.T. Mahajan, M. Sher, M. Naeem-ul-Hassan, and M.W. Amjad Synthesis of alpha, beta-unsaturated carbonyl based compounds as acetylcholinesterase and butyrylcholinesterase inhibitors: characterization, molecular modeling, QSAR studies and effect against amyloid beta-induced cytotoxicity Eur. J. Med. Chem. 83 2014 355 365
11. G.M. Casanola-Martin, Y. Marrero-Ponce, M.T. Khan, A. Ather, S. Sultan, F. Torrens, and R. Rotondo TOMOCOMD-CARDD descriptors-based virtual screening of tyrosinase inhibitors: evaluation of different classification model combinations using bond-based linear indices Bioorg. Med. Chem. 15 2007 1483 1503
12. G.M. Casanola-Martin, Y. Marrero-Ponce, M.T. Khan, S.B. Khan, F. Torrens, F. Perez-Jimenez, A. Rescigno, and C. Abad Bond-based 2D quadratic fingerprints in QSAR studies: virtual and in vitro tyrosinase inhibitory activity elucidation Chem. Biol. Drug Des. 76 2010 538 545
13. P. Csermely, T. Korcsmaros, H.J. Kiss, G. London, and R. Nussinov Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review Pharmacol. Ther. 138 2013 333 408
14. J.L. Cummings, T. Morstorf, and K. Zhong Alzheimer's disease drug-development pipeline: few candidates, frequent failures Alzheimers Res. Ther. 6 2014 37
15. N.V. Chawla, N. Japkowicz, and A. Kotcz Editorial: Special Issue on Learning from Imbalanced Data Sets vol. 6 2004 ACM Sigkdd Explorations Newsletter 1 6
16. A. Duardo-Sanchez, C.R. Munteanu, P. Riera-Fernandez, A. Lopez-Diaz, A. Pazos, and H. Gonzalez-Diaz Modeling complex metabolic reactions, ecological systems, and financial and legal networks with MIANN models based on Markov-Wiener node descriptors J. Chem. Inf. Model 54 2014 16 29
17. D. Erhan, P.J. L'Heureux, S.Y. Yue, and Y. Bengio Collaborative filtering on a family of biological targets J. Chem. Inf. Model 46 2006 626 635
18. J.P. Finberg, and M.B. Youdim Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours Neuropharmacology 43 2002 1110 1118
19. A. Garcia-Garcia, J. Galvez, J.V. de Julian-Ortiz, R. Garcia-Domenech, C. Munoz, R. Guna, and R. Borras New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method J. Antimicrob. Chemother. 53 2004 65 73
20. A. Gaulton, L.J. Bellis, A.P. Bento, J. Chambers, M. Davies, A. Hersey, Y. Light, S. McGlinchey, D. Michalovich, B. Al-Lazikani, and J.P. Overington ChEMBL: a large-scale bioactivity database for drug discovery Nucleic Acids Res. 40 2012 D1100 D1107
21. H. Gonzalez-Diaz, S. Arrasate, A.G. Juan, N. Sotomayor, E. Lete, A. Speck-Planche, J.M. Ruso, F. Luan, and M.N. Cordeiro Matrix trace operators: from spectral moments of molecular graphs and complex networks to perturbations in synthetic reactions, micelle nanoparticles, and drug ADME processes Curr. Drug Metab. 15 2014 470 488
22. H. Gonzalez-Diaz, S. Arrasate, N. Sotomayor, E. Lete, C.R. Munteanu, A. Pazos, L. Besada-Porto, and J.M. Ruso MIANN models in medicinal, physical and organic chemistry Curr. Top. Med. Chem. 13 2013 619 641
23. H. Gonzalez-Diaz, A. Duardo-Sanchez, F.M. Ubeira, F. Prado-Prado, L.G. Perez-Montoto, R. Concu, G. Podda, and B. Shen Review of MARCH-INSIDE & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers Curr. Drug Metab. 11 2010 379 406
24. H. Gonzalez Diaz, E. Olazabal, N. Castanedo, I.H. Sanchez, A. Morales, H.S. Serrano, J. Gonzalez, and R.R. de Armas Markovian chemicals "in silico" design (MARCH-INSIDE), a promising approach for computer aided molecular design II: experimental and theoretical assessment of a novel method for virtual screening of fasciolicides J. Mol. Model 8 2002 237 245
25. S.S. Haykin, S.S. Haykin, S.S. Haykin, and S.S. Haykin Neural Networks and Learning Machines 2009 Pearson Education Upper Saddle River
26. K. Heikamp, and J. Bajorath Large-scale similarity search profiling of ChEMBL compound data sets J. Chem. Inf. Model 51 2011 1831 1839
27. T. Hill, and P. Lewicki STATISTICS Methods and Applications. A Comprehensive Reference for Science 2006 Industry and Data Mining. StatSoft Tulsa
28. G.E. Hinton, S. Osindero, and Y.-W. Teh A fast learning algorithm for deep belief nets Neural Comput. 18 2006 1527 1554
29. Y.-C. Ho, and D.L. Pepyne Simple explanation of the no-free-lunch theorem and its implications J. Optim. Theory Appl. 115 2002 549 570
30. D.W. Howells, E.S. Sena, V. O'Collins, and M.R. Macleod Improving the efficiency of the development of drugs for stroke Int. J. Stroke 7 2012 371 377
31. Y. Hu, and J. Bajorath Molecular scaffolds with high propensity to form multi-target activity cliffs J. Chem. Inf. Model 50 2010 500 510
32. A. Lau, and M. Tymianski Glutamate receptors, neurotoxicity and neurodegeneration Pflugers Arch. 460 2010 525 542
33. Y. LeCun, Y. Bengio, and G. Hinton Deep learning Nature 521 2015 436 444
34. M. Leiros, E. Alonso, M.E. Rateb, W.E. Houssen, R. Ebel, M. Jaspars, A. Alfonso, and L.M. Botana Gracilins: Spongionella-derived promising compounds for Alzheimer disease Neuropharmacology 93 2015 285 293
35. F. Luan, M.N. Cordeiro, N. Alonso, X. Garcia-Mera, O. Caamano, F.J. Romero-Duran, M. Yanez, and H. Gonzalez-Diaz TOPS-MODE model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases Bioorg. Med. Chem. 21 2013 1870 1879
36. C. Lv, L. Wang, X. Liu, S. Yan, S.S. Yan, Y. Wang, and W. Zhang Multi-faced neuroprotective effects of geniposide depending on the RAGE-mediated signaling in an Alzheimer mouse model Neuropharmacology 89 2015 175 184
37. J. Ma, R.P. Sheridan, A. Liaw, G.E. Dahl, and V. Svetnik Deep neural nets as a method for quantitative structure-activity relationships J. Chem. Inf. Model 55 2015 263 274
38. Y. Marrero-Ponce, J.A. Castillo-Garit, E. Olazabal, H.S. Serrano, A. Morales, N. Castanedo, F. Ibarra-Velarde, A. Huesca-Guillen, A.M. Sanchez, F. Torrens, and E.A. Castro Atom, atom-type and total molecular linear indices as a promising approach for bioorganic and medicinal chemistry: theoretical and experimental assessment of a novel method for virtual screening and rational design of new lead anthelmintic Bioorg. Med. Chem. 13 2005 1005 1020
39. L.J. Martin Biology of mitochondria in neurodegenerative diseases Prog Mol Biol Transl Sci. 2012 2012 Elsevier Inc Netherlands 355 415
40. R.S. Michalski, J.G. Carbonell, and T.M. Mitchell Machine Learning: an Artificial Intelligence Approach 2013 Springer Science & Business Media
41. N.Y. Mok, and R. Brenk Mining the ChEMBL database: an efficient Cheminformatics workflow for assembling an ion channel-focused screening library J. Chem. Inf. Model 51 2011 2449 2454
42. H.R. Morris, A.J. Waite, N.M. Williams, J.W. Neal, and D.J. Blake Recent advances in the genetics of the ALS-FTLD complex Curr. Neurol. Neurosci. Rep. 12 2012 243 250
43. D. Moses, A. Gross, and J.P. Finberg Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig Neuropharmacology 47 2004 72 80
44. V. Namasivayam, Y. Hu, J. Balfer, and J. Bajorath Classification of compounds with distinct or overlapping multi-target activities and diverse molecular mechanisms using emerging chemical patterns J. Chem. Inf. Model 53 2013 1272 1281
45. A. Nurisso, C. Simoes-Pires, S. Martel, D. Cressend, A. Guillot, and P.A. Carrupt How to increase the safety and efficacy of compounds against neurodegeneration? A multifunctional approach Chim. (Aarau) 66 2012 286 290
46. J.D. Olden, M.K. Joy, and R.G. Death An accurate comparison of methods for quantifying variable importance in artificial neural networks using simulated data Ecol. Model. 178 2004 389 397
47. N.H. Park Parkinson disease JAAPA 25 2012 73 74
48. S.J. Patankar, and P.C. Jurs Classification of inhibitors of protein tyrosine phosphatase 1B using molecular structure based descriptors J. Chem. Inf. Comput. Sci. 43 2003 885 899
49. L. Pisani, R. Farina, O. Nicolotti, D. Gadaleta, R. Soto-Otero, M. Catto, M. Di Braccio, E. Mendez-Alvarez, and A. Carotti In silico design of novel 2H-chromen-2-one derivatives as potent and selective MAO-B inhibitors Eur. J. Med. Chem. 89 2015 98 105
50. M. Prince, E. Albanese, M. Guerchet, and M. Prina World Alzheimer Report 2014: Dementia and Risk Reduction. Alzheimer's Disease International. The Global Voice on Dementia 2014 104 pp
51. G. Rai, N. Joshi, J.E. Jung, Y. Liu, L. Schultz, A. Yasgar, S. Perry, G. Diaz, Q. Zhang, V. Kenyon, A. Jadhav, A. Simeonov, E.H. Lo, K. van Leyen, D.J. Maloney, and T.R. Holman Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies J. Med. Chem. 57 2014 4035 4048
52. O. Rascol, C.J. Fitzer-Attas, R. Hauser, J. Jankovic, A. Lang, J.W. Langston, E. Melamed, W. Poewe, F. Stocchi, and E. Tolosa A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes Lancet Neurol. 10 2011 415 423
53. F.J. Romero Duran, N. Alonso, O. Caamano, X. Garcia-Mera, M. Yanez, F.J. Prado-Prado, and H. Gonzalez-Diaz Prediction of multi-target networks of neuroprotective compounds with entropy indices and synthesis, assay, and theoretical study of new asymmetric 1,2-rasagiline carbamates Int. J. Mol. Sci. 15 2014 17035 17064
54. K. Roy, S. Kar, and R.N. Das Understanding the Basics of QSAR for Applications in Pharmaceutical Sciences and Risk Assessment 2015 Academic Press
55. M.E. Sahin, T. Can, and C.D. Son GPCRsort-responding to the next generation sequencing data challenge: prediction of G protein-coupled receptor classes using only structural region lengths Omics 18 2014 636 644
56. StatSoftInc STATISTICA (Data Analysis Software System), Version 6.0 2002 www.statsoft.com.Statsoft.Inc
57. E. Tenorio-Borroto, X. Garcia-Mera, C.G. Penuelas-Rivas, J.C. Vasquez-Chagoyan, F.J. Prado-Prado, N. Castanedo, and H. Gonzalez-Diaz Entropy model for multiplex drug-target interaction endpoints of drug immunotoxicity Curr. Top. Med. Chem. 13 2013 1636 1649
58. E. Tenorio-Borroto, F.R. Ramirez, A. Speck-Planche, M.N. Cordeiro, F. Luan, and H. Gonzalez-Diaz QSPR and flow cytometry analysis (QSPR-FCA): review and new findings on parallel study of multiple interactions of chemical compounds with immune cellular and molecular targets Curr. Drug Metab. 15 2014 414 428
59. E. Trushina, and C.T. McMurray Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases Neuroscience 2007 1233 1248 United States
60. J. Vergara-Galicia, F.J. Prado-Prado, and H. Gonzalez-Diaz Galvez-Markov network transferability indices: review of classic theory and new model for perturbations in metabolic reactions Curr. Drug Metab. 15 5 2014 557 564
61. L. Wang, G. Esteban, M. Ojima, O.M. Bautista-Aguilera, T. Inokuchi, I. Moraleda, I. Iriepa, A. Samadi, M.B. Youdim, A. Romero, E. Soriano, R. Herrero, A.P. Fernandez Fernandez, M. Ricardo Martinez, J. Marco-Contelles, and M. Unzeta Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease Eur. J. Med. Chem. 80 2014 543 561
62. M.A. Yildirim, K.I. Goh, M.E. Cusick, A.L. Barabasi, and M. Vidal Drug-target network Nat. Biotechnol. 25 2007 1119 1126
63. P. Zhang, and V. Brusic Mathematical modeling for novel cancer drug discovery and development Expert Opin. Drug Discov. 9 2014 1133 1150
64. H. Zheng, J. Hou, M.D. Zimmerman, A. Wlodawer, and W. Minor The future of crystallography in drug discovery Expert Opin. Drug Discov. 9 2014 125 137